CYP2C19*2 & *3 Detection Kit(RUO)

Clopidogrel ( Plavix), relating to disease: atherosclerotic events in patients with stroke, myocardial infarction or peripheral arterial vascular disease (e.g., myocardial infarction, stroke, or other death due to vascular disease)


In 2010, the U.S. FDA and Taiwan’s Department of Health published information on the use of Clopidogrel, requiring that generic versions of the drug include a boxed warning that the drug’s efficacy will be reduced in patients with the low metabolic activity of the liver enzyme CYP2C19, and that medical professionals should consider using other anticoagulant drugs or adjusting the dose.

Test Methods

Pharmigene, Inc. performs reagent development using TaqMan Real-Time PCR methodology and product validation using sequencing methods.

Online Enquiry

Satisfying your questions, needs, and requirements is always a priority.
The health of humanity is a responsibility that we will never relinquish.

HTML Snippets Powered By : XYZScripts.com
Scroll to Top